Change of Registered Office

RNS Number : 0412E
Hikma Pharmaceuticals Plc
03 May 2017
 

 

 

 

 

 

 

Hikma Changes Registered Office

 

 

 

London, 3 May 2017 - Hikma Pharmaceuticals PLC ("Hikma") (LEI:549300BNS685UXH4JI75)(LSE: HIK) (DIFX: HIK) today announces that its registered office has changed from 13 Hanover Square, London W1S 1HW to 1 New Burlington Place, London W1S 2HR with immediate effect. The move to 1 New Burlington Place creates the capacity Hikma requires to deliver its strategic plans.
 


 

 

-- ENDS --

 

Enquiries:

 

Hikma Pharmaceuticals PLC

 

Peter Speirs,

Company Secretary  

 

+44 (0)20 7399 2772

 

 

 

 

 

                   

 

Notes to Editors:

 

About Hikma

Hikma Pharmaceuticals PLC is a fast growing pharmaceutical group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products.  Hikma's operations are conducted through three businesses: "Branded", "Injectables" and "Generics" based primarily in the Middle East and North Africa ("MENA") region, where it is a market leader, the United States and Europe.  In 2016, Hikma achieved revenues of $1,950 million and profit attributable to shareholders of $155 million.


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
CROFMGGKLFKGNZG
UK 100

Latest directors dealings